Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Nephros (NEPH) EBITDA (2016 - 2025)

Nephros has reported EBITDA over the past 16 years, most recently at $18000.0 for Q4 2025.

  • Quarterly results put EBITDA at $18000.0 for Q4 2025, down 94.32% from a year ago — trailing twelve months through Dec 2025 was $1.1 million (up 2997.3% YoY), and the annual figure for FY2025 was $1.1 million, up 19000.0%.
  • EBITDA for Q4 2025 was $18000.0 at Nephros, down from $314000.0 in the prior quarter.
  • Over the last five years, EBITDA for NEPH hit a ceiling of $566000.0 in Q1 2025 and a floor of -$3.2 million in Q3 2022.
  • Median EBITDA over the past 5 years was -$375000.0 (2023), compared with a mean of -$593100.0.
  • Biggest five-year swings in EBITDA: plummeted 227.24% in 2022 and later skyrocketed 434.91% in 2025.
  • Nephros' EBITDA stood at -$1.1 million in 2021, then decreased by 2.71% to -$1.1 million in 2022, then surged by 42.38% to -$654000.0 in 2023, then surged by 148.47% to $317000.0 in 2024, then crashed by 94.32% to $18000.0 in 2025.
  • The last three reported values for EBITDA were $18000.0 (Q4 2025), $314000.0 (Q3 2025), and $248000.0 (Q2 2025) per Business Quant data.